Category: 3779-42-8

3779-42-8, 3-Bromo-N,N,N-trimethylpropan-1-aminium bromide is a catalyst-ligand compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

COMPOUHD 48; 5-(4-Nonyloxy-phenyl)-10J5,20-tris-[4-(3-trimethylammonio- propyloxy)-phenyl] -porphyrin trichloride; Compound 45 (50 mg, 0.062 mmol) and (3-bromopropyl)- trimethylammonium bromide (162mg, 0.62 mmol, lOeqv.) are dissolved and potassium carbonate (128 mg, 0.93 mmol, 15 eqv.) is suspended under argon in absolute DMF (30 mL) and the mixture is stirred at 550C for 12 h. The solvent is removed in vacuo at 5O0C and the residue re- dissolved in a little methanol and applied to a pad of silica (2 cm deep). The unreacted ammonium salts are washed off with methanol (lOOOmL). The product is eluted with acetic acid:methanol:water (3 :2:1 by vol.). The solvents are removed under reduced pressure and the product further purified by chromatography on a column (10Og) of Sephadex LH-20 eluting with n-butanol:water:acetic acid (4:5: 1 by vol., upper phase). The solvents are removed under reduced pressure, the residue re-dissolved in a little methanol and the solution is passed through a short column of anion exchange resin (Amberlite IRC 400, chloride form) using methanol as eluent. After removal of solvent, the product is dried at high vacuum o give a violet solid. 1H-NNZ[R: deltaH (300MHz, CD3OD): 0.89 (t, 3H, 3J= 7.5 Hz). 1.18-1.34 (m, 10H)5 1.41 (bs, 2H), 1.73 (quint 2H, 3J- 7.5 Hz), 2.30-2.44 (m, 6H), 3,31 (bs, 27H)5 3.65-3.73 (m, 6H)5 3.93 (t 2H, 3J = 7.5 Hz)5 4.25-4.42 (m, 6H), 7.08 (d, 2H5 3J= 7.5 Hz)5 7.30 (d, 6H, 3J= 7.5 Hz)5 7.93 (d, 2H5 3J= 7.5 Hz)5 8.05 (d, 6H5 3J= 7.5 Hz), 8.94 (bs, 8H)

3779-42-8, The synthetic route of 3779-42-8 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; DESTINY PHARMA LIMITED; WO2006/765; (2006); A1;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.3779-42-8,3-Bromo-N,N,N-trimethylpropan-1-aminium bromide,as a common compound, the synthetic route is as follows.

Compound 30 (100 mg, 0.12 mmol) is dissolved and K2CO3 (230 mg, 1.7 mmol) is suspended in DMF (30 mL). To the vigorously-stirred mixture a solution of (1-BROMOPROPYL)-TRIMETHYLAMMONIUM bromide (0.3 g, 16.6 mmol) in DMF (10 mL) is added dropwise at 50C during 30 mins and the mixture is heated for 18 h. After removal of DMF under reduced pressure, the residue obtained is dissolved in methanol (5 mL) and filtered through a pad of silica gel (depth 2 CM) supported on a steel frit (diameter 3.5 CM). After washing the pad with methanol (ca. 500 mL) it is eluted with acetic acid: methanol: water (3: 2: 1, by vol. ). After evaporation of solvent from appropriate combined fractions under reduced pressure, the residue is purified by chromatography on a column (2.5 x 40 CM) of Sephadex LH-20 eluting with n-butanol: water: acetic acid (5: 4: 1, by vol. , upper phase). After removal of solvent under reduced pressure from the eluate, the residue obtained is dissolved in methanol and the solution is passed through a short column (3.5 x 20 cm) of anion exchange resin (Amberlite IRA 400, chloride form). Evaporation of solvent from the eluate gives the product which is dried under high vacuum. 1H-NMR : aH (300MHZ, CD30D) : 0.75-0. 80 (m, 3 H), 1.00-1. 40 (m, 18 H), 1.60- 1.80 (bs, 2 H), 2.25-2. 40 (bs, 6 H), 3.29 (bs, 27 H), 3.40-3. 60 (m, 6 H), 3.90-4. 00 (m, 2 H), 4.05-4. 25 (m, 6 H), 7.10-7. 20,7. 25-7.40, 7.60-7. 80, 7.80-7. 90 (4 x m, 16H), 8.70-9. 00 (bs, 8 H)., 3779-42-8

The synthetic route of 3779-42-8 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; DESTINY PHARMA LIMITED; SOLVIAS AG; WO2004/56828; (2004); A2;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.3779-42-8,3-Bromo-N,N,N-trimethylpropan-1-aminium bromide,as a common compound, the synthetic route is as follows.

COMPOUKD 29; 5J0-bis-[4-(3-Trimethylammonio-propyloxy)-phenyl]-15,20-bis-(4- undecyloxy-phenyl)-porphyrin dichloride; Compound 14 (50 mg, 0.05 mmol) is dissolved and K2CO3 (150 mg, 1.1 mmol) is suspended in DMF (30 mL). To the vigorously- stirred mixture a solution of (l-bromopropyl)-trimethylammonium bromide (0.3 g, 16.6 mmol) in DMF (10 mL) is added dropwise at 500C and the mixture is heated for 18 h. After removal of DMF under high vacuum, the residue obtained is dissolved in methanol (5 mL) and filtered through a pad of silica gel (depth 2 cm) supported on a steel frit (diameter 3.5 cm). After washing the pad with methanol (ca. 500 mL) it is eluted with acetic acid:methanol:water (3 :2:1, by vol.). After evaporation of solvent from appropriate combined fractions the residue obtained is purified by chromatography on a column (2.5 x 40 cm) of Sephadex LH-20 eluting with n-butanol:water:acetic acid (5:4: 1, by vol.. upper phase) for further separation from the excess ammonium salt and other by-products. After removal of solvent under reduced pressure the residue obtained is dissolved in methanol and passed through a short column (3.5 x 20 cm) of anion exchange resin (Amberlite IRA 400, chloride form). After evaporation of solvent under reduced pressure, the product is dried under high vacuum.1H-NMR: deltaH (300MHz, CD3OD): 0.80 (t, 3J 7.5 Hz, 6 H), 1.15-1.35 (m, 28 H), 1.35-1.45 (bs, 4 H), 1.70-1.80 (bs, 4 H), 2.30-2.40 (bs, 4 H), 3.15-3.30 (bs, 18 H), 3.65-3.75 (bs5 4 H), 4.00-4.05 (m, 4 H), 4.30-4.40 (bs, 4 H), 7.00-7.15, 7.20-7.30, 7.80-95, 7.95-8.15 (4 x m, 4 x 4 H), 8.60-9.00 (bs, 8 H).

3779-42-8, As the paragraph descriping shows that 3779-42-8 is playing an increasingly important role.

Reference£º
Patent; DESTINY PHARMA LIMITED; WO2006/765; (2006); A1;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.3779-42-8,3-Bromo-N,N,N-trimethylpropan-1-aminium bromide,as a common compound, the synthetic route is as follows.

Compound 45 (50 mg, 0.062 mmol) and (3-bromopropyl)- trimethylammonium bromide (162mg, 0.62 mmol, LOEQV.) are dissolved and potassium carbonate (128 mg, 0.93 mmol, 15 eqv. ) is suspended under argon in absolute DMF (30 ML) and the mixture is stirred at 55C for 12 h. The solvent is removed in vacuo at 50C and the residue re- dissolved in a little methanol and applied to a pad of silica (2 cm deep). The unreacted ammonium salts are washed off with methanol (LOOOML). The product is eluted with acetic acid: methanol: water (3: 2: 1 by vol.). The solvents are removed under reduced pressure and the product further purified by chromatography on a column (lOOg) of Sephadex LH-20 eluting with n-butanol: water: acetic acid (4: 5: 1 by vol. , upper phase). The solvents are removed under reduced pressure, the residue re-dissolved in a little methanol and the solution is passed through a short column of anion exchange resin (Amberlite IRC 400, chloride form) using methanol as eluent. After removal of solvent, the product is dried at high vacuum to give a violet solid. 1H-NMR : 6H (300MHZ, CD30D) : 0. 89 (t, 3H, 3J= 7.5 Hz), 1.18-1. 34 (m, LOH), 1.41 (bs, 2H), 1.73 (quint, 2H, 3J= 7.5 Hz), 2.30-2. 44 (m, 6H), 3,31 (bs, 27H), 3.65-3. 73 (m, 6H), 3.93 (t, 2H, 3J= 7.5 Hz), 4.25-4. 42 (m, 6H), 7.08 (d, 2H, 3J= 7.5 Hz), 7. 30 (d, 6H, 3J= 7.5 Hz), 7.93 (d, 2H, 3J= 7.5 Hz), 8.05 (d, 6H, 3J= 7.5 Hz), 8.94 (bs, 8H)

3779-42-8, The synthetic route of 3779-42-8 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; DESTINY PHARMA LIMITED; SOLVIAS AG; WO2004/56828; (2004); A2;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.3779-42-8,3-Bromo-N,N,N-trimethylpropan-1-aminium bromide,as a common compound, the synthetic route is as follows.

COMPOUND 28; 5,15-bis-[3-(3-Trimethylammmonio-propylox)0-ph.enyl]-10-undecyl- porphyrin dichloride; To a solution of Compound 27 (50 mg, 0.08 mmol) in DMF (20 mL) under an argon atmosphere K2CO3 (100 mg, 0.72 mmol) and (3- bromopiOpyl)-trimethylammonium bromide (300 mg, 1.2 mmol) are added and the mixture is stirred at 500C for 18 h. After removal of solvent under high vacuum the residue obtained is dissolved in methanol (5 mL) and filtered through a pad of silica gel (depth 2 cm) supported on a steel frit (diameter 3.5 cm). After washing the pad with methanol (500 mL) it is eluted with acetic acid:methanol:water (3:2:1, v:v). After drying of appropriate combined fractions under high vacuum the residue is dissolved in methanol and purified by column chromatography on Sephadex LH-20 eluting with n-butanol: acetic acid: water (5: 1:4, by vol., upper phase). After evaporation of solvent the residue obtained from the first fraction eluted is dissolved in methanol and passed through a short column of anion exchange resin (Amberlite IRA 400. chloride form) to give, after evaporation of solvent, the pure product.1H-NMR: deltaH (300Mz, CD3OD): 0.85 (t, 3Z 7.5 Hz, 3 H), 1.20-1.40 (m, 12 H), 1.50 (m, 2 H), 1.80 (m, 2 H), 2.40 (bs, 4 H), 2.55 (m, 2 H), 3.20 (bs, 18 H), 3.65 (bs, 4 H), 4.35 (bs, 4 H), 5.10 (m, 2 H), 7.50-7.55, 7.70-7.85 (2 x m, 8 H), 8.95-9.00, 9.25-9.24, 9.50-9.70 (3 x bs, 8 H), 10.15 (bs5 IH).

3779-42-8, 3779-42-8 3-Bromo-N,N,N-trimethylpropan-1-aminium bromide 151145, acatalyst-ligand compound, is more and more widely used in various fields.

Reference£º
Patent; DESTINY PHARMA LIMITED; WO2006/765; (2006); A1;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

3779-42-8, 3-Bromo-N,N,N-trimethylpropan-1-aminium bromide is a catalyst-ligand compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

To a vigorously-stirred suspension of Compound 5 (80 mg, 0.14 mmol) and K2CO3 (230 mg, 1.7 mmol) in DMF (30 mL) is added (1- bromopropyl) -trimethylammonium bromide (0.3 g, 16.6 mmol) at 50 C. The mixture is stirred at this temperature for 18 h. After removal of the DMF under reduced pressure, the residue obtained is dissolved in methanol (5 mL) and filtered through a pad of silica gel (depth 2 cm) supported on a steel frit (diameter 3.5 cm). After washing the pad with methanol (ca. 1L) the crude product is eluted with acetic acid: methanol: water (3: 2: 1, by vol. ). Appropriate fractions are collected and, after evaporation of the solvent under reduced pressure, the residue obtained is purified by chromatography on a column (2.5 x 40 cm) of Sephadex LH-20 eluting with n-butanol: water: acetic acid (5: 4: 1, by vol., upper phase). After removal of the solvent from appropriate fractions under reduced pressure, the residue obtained is dissolved in methanol (5 mL) and the solution is passed through a short column (3.5 x 20 cm) of anion exchange resin (Amberlite IRA 400, chloride form). After collection of the eluate, solvent is removed under reduced pressure and the residue obtained is dried under high vacuum to yield the dichloride salt as violet crystals. 1H-NMR : 6H (300MZ, CD30D) : 0.75 (T, 3J7. 5 Hz, 3 H), 1.05-1. 20 (m, 14 H), 1.45- 1.50 (m, 2 H), 2.05-2. 15 (m, 4 H), 2.15-2. 20 (m, 2 H), 2.95 (s, 18 H), 3.35-3. 45 (m, 4 H), 3.95 (T, 3J7. 5 Hz, 4 H), 4.55 (t, 3J7. 5 Hz, 2 H), 6. 85 (m, 1 H), 7.35 (m, 2 H), 8.85-8. 90,9. 15-9.20, (3 X M, 8 H), 10.10 (s, 2 H).

3779-42-8, The synthetic route of 3779-42-8 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; DESTINY PHARMA LIMITED; SOLVIAS AG; WO2004/56828; (2004); A2;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI